# A Study of LY900014 Formulation in Healthy Participants

> **NCT02942654** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LY900014
- **DRUG:** Insulin Lispro

## Key facts

- **NCT ID:** NCT02942654
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02942654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02942654, "A Study of LY900014 Formulation in Healthy Participants". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT02942654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*